Innovation in bone healing and tissue repair

Dr. Christian Itin - Chairman

Christian Itin serves as Kuros Chairman of the Board (“Chairman”) since the completion of the merger of Kuros Biosurgery with Cytos Biotechnology in January 2016. Dr. Itin is CEO and Chairman of Autolus Inc., London, UK, since March 2016 and November 2014, respectively. From November 2012 to January 2016, he served as Chairman and CEO of Cytos Biotechnology. Before joining Cytos, Dr. Itin was President and CEO of Micromet Inc., which was acquired in 2012 by Amgen, Inc. Over a period of 13 years, he served in a number of senior management roles at Micromet, becoming CEO in 2004. Dr. Itin received a diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he performed post-doctoral research at the Biocenter of Basel University, Switzerland, and at Stanford University School of Medicine, Stanford, California, USA. Dr. Itin also serves as non-executive director of Kymab Ltd, Cambridge, UK. Christian Itin is a Swiss citizen and resident of Germany.

Professor Clemens van Blitterswijk

Professor Clemens van Blitterswijk, PhD, is the Department Chair and Professor at MERLN Institute for Technology-Inspired Regenerative Medicine at Maastricht University, The Netherlands. Prof van Blitterswijk has founded nine companies over the years. He is recipient of numerous national and international awards like recently “the most entrepreneurial professor of the Netherlands”. He brings over two decades of entrepreneurial science to the Kuros team. Prof van Blitterswijk has authored and co-authored over 350 scientific papers and is inventor on more than 100 patents. He has published three books as an editor, and contributed to many more as a contributing author. Prof van Blitterswijk is a biologist by training and has a PhD in Medicine from Leiden University, The Netherlands. He is Dutch citizen.

Leanna Caron

Leanna Caron is Executive Vice President and Chief Commercial Officer for AgNovos Healthcare, a company focused on bone health. In this role, Ms. Caron oversees all aspects of commercial development, launch and corporate communications. A seasoned executive, Ms. Caron developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management. Prior to her current role, Ms. Caron was Vice President and General Manager at Sanofi, overseeing the global commercial operations for Cell Therapy and Regenerative Medicine. She has also held senior positions at Genzyme and Merck in the United States, Canada, and Europe and has led several international teams to successfully launch niche/orphan and block-buster products globally. Ms. Caron has served on the boards of WomenLead and CartiHeal, and currently serves as a strategic advisor to the board of CartiHeal, and is Chairman of the Board and President of Skate Canada. She received her pharmacy degree from the University of Toronto, Canada, and her MBA from Concordia University, Montreal, Canada, and Cornell University, Ithaca/NY, USA. Mrs. Caron is citizen of Canada.

Dr. Ivan Cohen-Tanugi

Dr. Ivan Cohen-Tanugi has been named Chief Executive Officer of Kuros in April 2017. He joined the Company with more than 20 years of experience in leadership roles in the life sciences industry. Dr. Cohen-Tanugi held various managing positions at Sanofi, Roche, Amgen, Teva, Eyevensys and Stallergenes-Greer including as Head of Amgen Europe Nephrology, General Manager Teva North America Biologics & Specialty and CEO of Eyevensys. He received his medical degree at Grenoble School of Medicine, France, and obtained a MBA at H.E.C. Business School, Paris, France. Dr. Cohen-Tanugi is French and US citizen.

Didier Cowling

Didier Cowling co-founded Kuros in early 2002 and has been its CEO until April 2017. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Giacomo Di Nepi

Giacomo Di Nepi brings over 30 years’ experience in the industry. Currently, he is CEO of Polyphor Ltd, Allschwil, Switzerland. Before, he was Executive Vice President and General Manager, Europe for InterMune Inc., where he launched Esbriet, an orphan drug, and built from scratch a USD 140 million and 200 people business – until the acquisition of InterMune by Roche for USD 8.3 billion. Previously, Mr. Di Nepi was in senior leadership responsibilities with Takeda and Novartis, where he was member of the Pharma Executive Committee. Prior, he was a Partner with McKinsey. Mr. Di Nepi currently serves on the boards of Geneuro (GNRO.PA) and NTC, a privately held company. He holds a degree in Economics from Bocconi University, Milan, Italy, and an MBA from INSEAD, Fontainebleau, France. Mr. Di Nepi is Italian citizen.

Dr. Gerhard Ries

Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharmaceutical industry and venture capital experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Before founding LifeCare Partners, Gerhard was co-founder and managing partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies. Gerhard’s current board memberships include DiaMedCare, Devis Pharma, Leon Nanodrugs, Leukocare and AOInvest. Dr. Ries holds a MS and a PhD degree in Molecular Biology from the University of Basel, Switzerland, and a MS degree in Biotechnology from the Fachhochschule Weihenstephan, Munich, Germany. Mr. Ries is Swiss and German citizen.

Frank-Jan van der Velden

Frank-Jan van der Velden, MBA, co-founded Xpand Biotechnology (“Xpand”) in 2005, which became a wholly owned subsidiary of Kuros Biosciences in January 2017, and has been a member of Kuros’ Executive Committee since the acquisition. He was co-founder of several other companies in the field of regenerative medicine amongst others CellCoTec, Progentix Orthobiology and Materiomics. Prior to co-founding Xpand, Mr. van der Velden was partner at Krüger & Partners management consultants for ten years after 10 years as director of Quote Media Holding. Currently, he is chairman of the supervisory board of TIIN Techfund III (venture capital fund for technology start-ups), board member of RiverDiagnostics International (a manufacturer of Raman spectroscopy equipment for life science application) and member of the executive committee of Materiomics (high-throughput screening for cell-surface topography interaction). Mr. van der Velden is a graduate of Erasmus University Rotterdam School of Management, The Netherlands. He is a Dutch citizen.

Harry Welten

Harry Welten is Chief Financial Officer (“CFO”) of Kuros. From June 2010 to January 2016 he served as executive vice president and CFO of Cytos. He has more than 20 years of international senior executive experience, sixteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the CFO at Nitec Pharma, which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the CFO at Arpida, which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a director at UBS Warburg in New York/NY, USA, following various senior positions within the UBS Group. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Anokion, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York/NY, USA. Mr. Welten is Swiss citizen.

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Executive Committee
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Board

Dr. Christian Itin
Chairman

Christian Itin serves as Kuros Chairman of the Board (“Chairman”) since the completion of the merger of Kuros Biosurgery with Cytos Biotechnology in January 2016. Dr. Itin is CEO and Chairman of Autolus Inc., London, UK, since March 2016 and November 2014, respectively. From November 2012 to January 2016, he served as Chairman and CEO of Cytos Biotechnology. Before joining Cytos, Dr. Itin was President and CEO of Micromet Inc., which was acquired in 2012 by Amgen, Inc. Over a period of 13 years, he served in a number of senior management roles at Micromet, becoming CEO in 2004. Dr. Itin received a diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he performed post-doctoral research at the Biocenter of Basel University, Switzerland, and at Stanford University School of Medicine, Stanford, California, USA. Dr. Itin also serves as non-executive director of Kymab Ltd, Cambridge, UK. Christian Itin is a Swiss citizen and resident of Germany.

Professor Clemens van Blitterswijk

Professor Clemens van Blitterswijk, PhD, is the Department Chair and Professor at MERLN Institute for Technology-Inspired Regenerative Medicine at Maastricht University, The Netherlands. Prof van Blitterswijk has founded nine companies over the years. He is recipient of numerous national and international awards like recently “the most entrepreneurial professor of the Netherlands”. He brings over two decades of entrepreneurial science to the Kuros team. Prof van Blitterswijk has authored and co-authored over 350 scientific papers and is inventor on more than 100 patents. He has published three books as an editor, and contributed to many more as a contributing author. Prof van Blitterswijk is a biologist by training and has a PhD in Medicine from Leiden University, The Netherlands. He is Dutch citizen.

Leanna Caron

Leanna Caron is Executive Vice President and Chief Commercial Officer for AgNovos Healthcare, a company focused on bone health. In this role, Ms. Caron oversees all aspects of commercial development, launch and corporate communications. A seasoned executive, Ms. Caron developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management. Prior to her current role, Ms. Caron was Vice President and General Manager at Sanofi, overseeing the global commercial operations for Cell Therapy and Regenerative Medicine. She has also held senior positions at Genzyme and Merck in the United States, Canada, and Europe and has led several international teams to successfully launch niche/orphan and block-buster products globally. Ms. Caron has served on the boards of WomenLead and CartiHeal, and currently serves as a strategic advisor to the board of CartiHeal, and is Chairman of the Board and President of Skate Canada. She received her pharmacy degree from the University of Toronto, Canada, and her MBA from Concordia University, Montreal, Canada, and Cornell University, Ithaca/NY, USA. Mrs. Caron is citizen of Canada.

Dr. Ivan Cohen-Tanugi

Dr. Ivan Cohen-Tanugi has been named Chief Executive Officer of Kuros in April 2017. He joined the Company with more than 20 years of experience in leadership roles in the life sciences industry. Dr. Cohen-Tanugi held various managing positions at Sanofi, Roche, Amgen, Teva, Eyevensys and Stallergenes-Greer including as Head of Amgen Europe Nephrology, General Manager Teva North America Biologics & Specialty and CEO of Eyevensys. He received his medical degree at Grenoble School of Medicine, France, and obtained a MBA at H.E.C. Business School, Paris, France. Dr. Cohen-Tanugi is French and US citizen.

Didier Cowling

Didier Cowling co-founded Kuros in early 2002 and has been its CEO until April 2017. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Giacomo Di Nepi

Giacomo Di Nepi brings over 30 years’ experience in the industry. Currently, he is CEO of Polyphor Ltd, Allschwil, Switzerland. Before, he was Executive Vice President and General Manager, Europe for InterMune Inc., where he launched Esbriet, an orphan drug, and built from scratch a USD 140 million and 200 people business – until the acquisition of InterMune by Roche for USD 8.3 billion. Previously, Mr. Di Nepi was in senior leadership responsibilities with Takeda and Novartis, where he was member of the Pharma Executive Committee. Prior, he was a Partner with McKinsey. Mr. Di Nepi currently serves on the boards of Geneuro (GNRO.PA) and NTC, a privately held company. He holds a degree in Economics from Bocconi University, Milan, Italy, and an MBA from INSEAD, Fontainebleau, France. Mr. Di Nepi is Italian citizen.

Dr. Gerhard Ries

Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharmaceutical industry and venture capital experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Before founding LifeCare Partners, Gerhard was co-founder and managing partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies. Gerhard’s current board memberships include DiaMedCare, Devis Pharma, Leon Nanodrugs, Leukocare and AOInvest. Dr. Ries holds a MS and a PhD degree in Molecular Biology from the University of Basel, Switzerland, and a MS degree in Biotechnology from the Fachhochschule Weihenstephan, Munich, Germany. Mr. Ries is Swiss and German citizen.

Frank-Jan van der Velden

Frank-Jan van der Velden, MBA, co-founded Xpand Biotechnology (“Xpand”) in 2005, which became a wholly owned subsidiary of Kuros Biosciences in January 2017, and has been a member of Kuros’ Executive Committee since the acquisition. He was co-founder of several other companies in the field of regenerative medicine amongst others CellCoTec, Progentix Orthobiology and Materiomics. Prior to co-founding Xpand, Mr. van der Velden was partner at Krüger & Partners management consultants for ten years after 10 years as director of Quote Media Holding. Currently, he is chairman of the supervisory board of TIIN Techfund III (venture capital fund for technology start-ups), board member of RiverDiagnostics International (a manufacturer of Raman spectroscopy equipment for life science application) and member of the executive committee of Materiomics (high-throughput screening for cell-surface topography interaction). Mr. van der Velden is a graduate of Erasmus University Rotterdam School of Management, The Netherlands. He is a Dutch citizen.

Harry Welten

Harry Welten is Chief Financial Officer (“CFO”) of Kuros. From June 2010 to January 2016 he served as executive vice president and CFO of Cytos. He has more than 20 years of international senior executive experience, sixteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the CFO at Nitec Pharma, which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the CFO at Arpida, which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a director at UBS Warburg in New York/NY, USA, following various senior positions within the UBS Group. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Anokion, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York/NY, USA. Mr. Welten is Swiss citizen.